“With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.”
CrownBio clients will be now able to manage their internal patient-derived xenograft (PDX) portfolio on the model of CrownBio’s bespoke HuBase technology platform.
CrownBio intends to expand characterization, including next generation sequencing, of the models, and ultimately to develop new models resistant to current clinical therapies.
2 of 2
Receive JSR Life Sciences news on your RSS reader.